Request Sample
Request Methodology
Description
Prescribed medication for acute treatment for migraine market valued US 1,970.0 Mn in 2021 and is poised to grow with a CAGR of 14.6% over 2022-2028. This report gives comprehensive outlook on prescribed medication for acute treatment for migraine across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The report on global market gives historical, current, and future market sizes (US$ Mn) on the basis of drug type, route of administration, distribution channel and region. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global prescribed medication for acute treatment for migraine market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policymakers, and service providers engaged in global prescribed medication for acute treatment for migraine products. Abortive accounted for larger revenue share in the global market with a CAGR of 14.6% and is expected to grow over the forecast years. This is due to the ease of self-administration in case of patients with symptoms of nausea and vomiting along with migraine. This market is surging owing to expansion of their production facilities for prescribed medication for acute treatment for migraine to meet the demands of the customers in the market. For instance, In June 2017, AstraZeneca announced that company has entered an agreement with Grünenthal for the global rights to Zomig (zolmitriptan) outside Japan. In 2014, Endo International plc announced that affiliates of the company have acquired worldwide rights to Sumavel® DosePro® (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc. In May 2018, Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention.
